Shah Pritesh's Form 4 filing
NovoCure Ltd (NVCR) · filed Sep 7, 2021
- Accession no.
- 0001645113-21-000106
- Filed
- Sep 7, 2021
- Trade date
- Sep 2-3, 2021
- Filing delay
- 5 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 4 non-derivative transactions. Open-market sales total $91.0K. It was filed 5 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Shah PriteshCIK 0001744884 | Officer (Chief Commercial Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 2, 2021 | Ordinary Shares | SSaleDisposed | −156 | $138.23 | −$21,563.88 | 74,013 | Direct | |
| Sep 3, 2021 | Ordinary Shares | SSaleDisposed | −321 | $138.27 | −$44,384.67 | 73,692 | Direct | |
| Sep 3, 2021 | Ordinary Shares | SSaleDisposed | −150 | $139.24 | −$20,886 | 73,542 | Direct | |
| Sep 3, 2021 | Ordinary Shares | SSaleDisposed | −30 | $140.18 | −$4,205.4 | 73,512 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.